(NASDAQ: OKYO) Okyo Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 120.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 113.78%.
Okyo Pharma's earnings in 2026 is -$4,613,341.On average, 5 Wall Street analysts forecast OKYO's earnings for 2026 to be -$8,367,699, with the lowest OKYO earnings forecast at -$10,175,061, and the highest OKYO earnings forecast at -$7,267,901. On average, 3 Wall Street analysts forecast OKYO's earnings for 2027 to be -$13,336,021, with the lowest OKYO earnings forecast at -$12,813,039, and the highest OKYO earnings forecast at -$13,728,257.
In 2028, OKYO is forecast to generate -$12,551,549 in earnings, with the lowest earnings forecast at -$12,059,331 and the highest earnings forecast at -$12,920,712.